hl-085
Showing 1 - 9 of 9
Neurofibromatosis 1, Plexiform Neurofibromas Trial in Shanghai (HL-085)
Recruiting
- Neurofibromatosis 1
- Plexiform Neurofibromas
- HL-085
-
Shanghai, Shanghai, ChinaShanghai Ninth People's Hospital, Shanghai JiaoTong University S
Apr 10, 2022
Melanoma Trial in Beijing (HL-085)
Recruiting
- Melanoma
- HL-085
-
Beijing, Beijing, China
- +1 more
Jan 19, 2022
CRC Trial in Beijing (HL-085, Vemurafenib)
Not yet recruiting
- CRC
- HL-085
- Vemurafenib
-
Beijing, Beijing, ChinaBeijing Oncology Hospital
Feb 6, 2022
Nsclc Trial in Beijing (HL-085, Docetaxel)
Terminated
- Nsclc
- HL-085
- Docetaxel
-
Beijing, ChinaCancer Hospital Chinese Academy of Medical Science
Nov 29, 2021
Melanoma Trial in Beijing, Shanghai (HL-085)
Recruiting
- Melanoma
- HL-085
-
Beijing, Beijing, China
- +1 more
Dec 16, 2021
Solid Tumor, Adult Trial in United States (HL-085)
Recruiting
- Solid Tumor, Adult
- HL-085
-
San Marcos, California
- +4 more
Mar 17, 2021
Solid Tumor, Adult Trial in Austin, San Antonio (HL-085)
Terminated
- Solid Tumor, Adult
- HL-085
-
Austin, Texas
- +1 more
Nov 16, 2020